Preclinical data showed that regorafenib inhibited tumor angiogenesis, stroma formation and also tumor cells growth through targeting VEGFRs (vascular endothelial growth factor receptors) 1, 2 and 3, tyrosine-protein kinase receptor TIE-2, PDGFR (platelet-derived growth factor receptor)-β, FGF (fibroblast growth factor) receptor 1, proto-oncogene tyrosine-protein kinase receptor Ret, mast/stem cell growth factor receptor Kit and RAS/RAF/MEK/ERK pathway, proto-oncogene serine/threonine-protein kinase B-raf [5–8]. The gene discussed is KIT; the disease is neoplasm.